Doximity (DOCS) Research & Development (2020 - 2026)

Doximity (DOCS) has reported Research & Development for 7 consecutive years, with $45.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 23.88% year-over-year to $45.0 million in Q2 2026; TTM through Jun 2026 was $172.3 million, a 17.37% increase from a year earlier, with the FY2026 full-year figure at $163.6 million, up 12.31% from the prior year.
• Research & Development was $45.0 million for Q2 2026 at Doximity, down from $45.9 million in the prior quarter.
• Over five years, Research & Development peaked at $45.9 million in Q1 2026 and troughed at $25.9 million in Q1 2022.
• A 5-year average of $35.4 million and a median of $34.7 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 47.27% in 2022 and increased 1.11% in 2024, its largest moves.
• Over 5 years, Research & Development stood at $33.2 million in 2022, then increased by 5.23% to $35.0 million in 2023, then gained by 10.11% to $38.5 million in 2024, then increased by 9.65% to $42.2 million in 2025, then rose by 6.74% to $45.0 million in 2026.
• The last three Research & Development figures came in at $45.0 million (Q2 2026), $45.9 million (Q1 2026), and $42.2 million (Q4 2025), per Business Quant data.